175
Participants
Start Date
January 31, 2015
Primary Completion Date
December 12, 2018
Study Completion Date
December 12, 2018
Combination of varlilumab and nivolumab
"Phase I: Varlilumab dosing will be dependent on the cohort assigned in combination with 3 mg/kg of nivolumab every two weeks.~Phase II: Patients with CRC, RCC or GBM enrolled in Phase ll will receive 3.0 mg/kg of varlilumab in combination with 240 mg of nivolumab every 2 weeks. Patients with SCCHN or ovarian cancer will receive varlilumab at a dose of either 3 mg/kg every 2 weeks, 3 mg/kg every 12 weeks, or 0.3 mg/kg every 4 weeks, in combination with 240 mg of nivolumab every 2 weeks.~Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects."
Laura and Isaac Perlmutter Cancer Center, New York
Columbia University Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
Georgetown University, Washington D.C.
George Washington University School of Medicine and Health Sciences, Washington D.C.
Inova Schar Cancer Institute Research, Fairfax
Wake Forest Baptist Health, Winston-Salem
Northwest Georgia Oncology Centers PC, Marietta
Mount Sinai Medical Center, Miami Beach
Cleveland Clinic, Cleveland
Parkview Research Center, Fort Wayne
Barbara Ann Karmanos Cancer Institute, Detroit
University of Colorado Medical Center, Aurora
University of Arizona Cancer Center, Tucson
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
The Stanford Center for Clinical and Translational Education and Research, Palo Alto
Providence Health & Services, Portland
Smilow Cancer Hospital at Yale University Cancer Center, New Haven
Dana Farber Cancer Institute, Boston
Lead Sponsor
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Celldex Therapeutics
INDUSTRY